References in periodicals archive ?
With clinical benefit response, we are able to demonstrate the benefits of drugs that provide improvements in certain disease-related symptoms, in addition to increasing survival time, for some patients.
Of 39 evaluable patients who received a dose of 20mg/m(2), 18 percent achieved an overall response and 26 percent achieved a clinical benefit response.
Secondary objectives of this study include safety and tolerability, clinical benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study.
This randomized trial demonstrated that the addition of ELOXATIN to gemcitabine, the current standard chemotherapy for pancreatic cancer, achieved significantly better results than gemcitabine alone in terms of response rate, progression-free survival and clinical benefit response.

Full browser ?